Quince Therapeutics, Inc.
QNCX
$34.04
$1.635.03%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -16.51% | -14.41% | -1.31% | -5.27% | 5.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.22% | 39.42% | 38.86% | 40.85% | 54.35% |
| Operating Income | -20.22% | -39.42% | -38.86% | -40.85% | -54.35% |
| Income Before Tax | 41.91% | -42.34% | -7.10% | 7.75% | -100.70% |
| Income Tax Expenses | -2,208.74% | 3,594.25% | -42.75% | 13.56% | 25.61% |
| Earnings from Continuing Operations | 45.58% | -47.78% | -6.97% | 7.71% | -100.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.58% | -47.78% | -6.97% | 7.71% | -100.49% |
| EBIT | -20.22% | -39.42% | -38.86% | -40.85% | -54.35% |
| EBITDA | -20.39% | -39.75% | -40.58% | -42.15% | -55.72% |
| EPS Basic | 32.59% | -25.04% | 2.13% | 13.38% | -83.89% |
| Normalized Basic EPS | 1.38% | -78.07% | -57.13% | -61.07% | -50.95% |
| EPS Diluted | 27.46% | -25.04% | 2.13% | 13.38% | -83.89% |
| Normalized Diluted EPS | 1.18% | -78.07% | -57.13% | -61.07% | -50.95% |
| Average Basic Shares Outstanding | 42.27% | 15.72% | 10.54% | 8.72% | 11.43% |
| Average Diluted Shares Outstanding | 42.67% | 15.72% | 10.54% | 8.72% | 11.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |